Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015 Nov 1;8(11):14709-16.
eCollection 2015.

Diagnostic utility of PAX2 and PAX5 in distinguishing non-small cell lung cancer from small cell lung cancer

Yinlong Ren  1 , Junna Hou  1 , Aiguo Xu  1 , Yunbao Pan  2
Affiliations

Diagnostic utility of PAX2 and PAX5 in distinguishing non-small cell lung cancer from small cell lung cancer

Yinlong Ren et al. Int J Clin Exp Pathol. .

Abstract

Lung cancer is the leading cause of cancer-related death in both men and women and consists of different histological types. Histopathological examination and accurate subtype diagnosis has become increasingly important in guiding patient management and, as such, is the most important currently available lung cancer "biomarker". In this study, we examined the expression of PAX2 and PAX5 by immunohistochemistry in 47 cases of lung cancer and 13 cases of pneumonia. The results demonstrated that PAX2 were detected in 82.8% (24/29) of NSCLC, 0% (0/18) of SCLC and 7.7% (1/13) of pneumonia, respectively; However, PAX5 were detected in 15/18 cases (83.3%) of SCLC, 6.8% (2/29) of NSCLC and 7.7% (1/13) of pneumonia. Further, the samples with lymphatic metastasis had remarkable higher positive PAX2 or PAX5 than that without metastases. Overall, our data indicated that PAX2 and PAX5 differentially expressed in NSCLC and SCLC. Thus, PAX2 and PAX5 are useful biomarker in the differential diagnosis of lung cancer.

Keywords: Lung cancer; PAX2; PAX5; biomarker; immunohistochemistry.

PubMed Disclaimer

Figures

Figure 1
Figure 1
HE staining of pneumonia and lung cancer tissue. A. Pneumonia. B. SCLC. C. Adenocarcinoma. D. Squamous cell carcinoma.
Figure 2
Figure 2
Expression patterns of PAX2 in pneumonia and lung cancer tissue. A. Pneumonia. B. SCLC. C. Adenocarcinoma. D. Squamous cell carcinoma.
Figure 3
Figure 3
Expression patterns of PAX5 in pneumonia and lung cancer tissue. A. Pneumonia. B. SCLC. C. Adenocarcinoma. D. Squamous cell carcinoma.
See this image and copyright information in PMC

References

    1. Abidoye O, Ferguson MK, Salgia R. Lung carcinoma in African Americans. Nat Clin Pract Oncol. 2007;4:118–129. - PubMed
    1. Robson EJ, He SJ, Eccles MR. A PANorama of PAX genes in cancer and development. Nat Rev Cancer. 2006;6:52–62. - PubMed
    1. Bouchard M, Souabni A, Mandler M, Neubuser A, Busslinger M. Nephric lineage specification by Pax2 and Pax8. Genes Dev. 2002;16:2958–2970. - PMC - PubMed
    1. Grote D, Souabni A, Busslinger M, Bouchard M. Pax 2/8-regulated Gata 3 expression is necessary for morphogenesis and guidance of the nephric duct in the developing kidney. Development. 2006;133:53–61. - PubMed
    1. Narlis M, Grote D, Gaitan Y, Boualia SK, Bouchard M. Pax2 and pax8 regulate branching morphogenesis and nephron differentiation in the developing kidney. J Am Soc Nephrol. 2007;18:1121–1129. - PubMed

Publication types

LinkOut - more resources